12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TRV130: Phase I data

A single-blind, placebo-controlled, U.S. Phase I trial in 74 healthy males showed that single ascending-doses of IV TRV130 were generally well tolerated, "rapidly" entered the CNS and...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >